Another ADC Buyout - Just not SPL, page-18

Merck publicly announcing it is ready to splash additional cash anywhere from $1 billion to $15 billion to increase / diversify its pipeline ..... Starpharma continually tout this Merck partnership (signed research agreements) and have even linked Keytruda® in announcements as far back as 29 June 2020 ..... with multiple Starpharma research agreements signed with Merck, the big question is why aren't they splashing any cash in our direction ?


This month marks 3 years (12 Feb 2021) since the first Merck / Starpharma research agreement was signed and to date Starpharma haven't received one cent in cash payments from Merck ? The Merck CEO publicly bragging about billions of dollars earmarked for deals and Starpharma thus far not receiving one cent might suggest that they are just not that interested in what they have seen in their research over the 3 year period ?



https://www.fiercepharma.com/pharma/merck-still-market-deals-1b-15b-range-ceo-says


Feb 1, 2024 11:01am
Merck still in the market for deals in the $1B to $15B range, CEO says


Merck made the biopharma industry’s second-largest deal of 2021 when it acquired Acceleron for $11.5 billion. Last year, Merck’s $10.8 billion buyout of Prometheus was the third-largest in the industry.

So what now for the New Jersey pharma giant as it gets another year closer to its date of reckoning, 2028, when it loses patent protection for cancer superstar Keytruda.

“While I feel very good about the progress we’ve made in growing the deep and diverse portfolio we have in our pipeline, we do believe we need more,” Merck CEO Rob Davis said in a quarterly conference call. “We will continue to prioritize business development. Our view of deals like Prometheus, like Acceleron are still the size of deals we are very interested in if we can find great assets.”


https://starpharma.com/assets/asxan...DEP ADC Research Agreement with MSD final.pdf


https://starpharma.com/news/682